BeOne Medicines (BEIGF) Accumulated Expenses (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Accumulated Expenses data on file, last reported at $1.1 billion in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $1.1 billion, up 55.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 55.93% YoY), and the FY2025 annual result was $1.1 billion, up 38.0% from the prior year.
• Accumulated Expenses retreated to $1.1 billion in Q1 2026 per BEIGF's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $1.1 billion in Q4 2025 and troughed at $386.0 million in Q1 2022.
• A 5-year average of $674.7 million and a median of $646.5 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses rose 0.17% in 2023, then jumped 55.93% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $619.5 million in 2022, then rose by 11.99% to $693.7 million in 2023, then grew by 15.85% to $803.7 million in 2024, then soared by 38.0% to $1.1 billion in 2025, then fell by 2.69% to $1.1 billion in 2026.
• Business Quant data shows BEIGF's Accumulated Expenses at $1.1 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.